Select Bibliography

 Search for any words:
Excel csv Word PDF RIS
  Filter by any of these (after searching):
      
Year
      
PubType
      
Endpoint
      
Analysis
      
Datasharing
Leukemia
Committee
      
Program
      
Meeting
      
Funding
                            

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 128 items

Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720 Google Scholar
,  ,  ... -  ASCO   -  J Clin Oncol   -  2008    
Abstract -  Secondary -  Primary -  Leukemia -  CALGB-10201 ,  CALGB-10502 ,  CALGB-10503 ,  CALGB-10603 ,  CALGB-19808 ,  CALGB-8525 ,  CALGB-8923 ,  CALGB-9022 ,  CALGB-9222 ,  CALGB-9420 ,  CALGB-9621 ,  CALGB-9720
Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101 Google Scholar
,  ,  ,  ,  ... -  ASH   -  Blood   -  2009    
Abstract -  Primary -  Primary -  Leukemia -  CALGB-10101


Copyright ©2013 - 2023 Alliance Foundation. All rights reserved.